CW Advisors LLC Raises Position in Danaher Corporation $DHR

Key Points

• CW Advisors LLC increased its stake in Danaher Corporation by 115.9%, acquiring an additional 14,775 shares to bring its total to 27,524 shares valued at $5.68 million.
• Danaher reported strong quarterly earnings with an EPS of $1.80, surpassing estimates by $0.16, and achieved a revenue of $5.94 billion.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" on Danaher, with a consensus target price of $247.61.

CW Advisors LLC grew its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 115.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 27,524 shares of the conglomerate's stock after acquiring an additional 14,775 shares during the quarter. CW Advisors LLC's holdings in Danaher were worth $5,678,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares during the period. Bank of New York Mellon Corp raised its holdings in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares during the period. Northern Trust Corp raised its holdings in Danaher by 14.3% during the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after buying an additional 992,594 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after buying an additional 579,046 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on DHR. Evercore ISI reduced their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. UBS Group cut their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Barclays reiterated an "overweight" rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Wells Fargo & Company lowered their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Trading Down 0.6%

Shares of Danaher stock traded down $1.29 during trading hours on Wednesday, hitting $204.96. The company's stock had a trading volume of 2,499,953 shares, compared to its average volume of 4,190,984. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm has a fifty day moving average of $201.02 and a 200-day moving average of $199.43. The stock has a market cap of $146.76 billion, a price-to-earnings ratio of 43.61, a P/E/G ratio of 2.90 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the business earned $1.72 EPS. Danaher's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.